Rasna Therapeutics, Inc. (RASP) financial statements (2021 and earlier)

Company profile

Business Address 420 LEXINGTON AVENUE
NEW YORK, NY 10170
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28505842884320
Cash and cash equivalents28505842884320
Receivables 142977133238105
Other undisclosed current assets8732436767162
Total current assets:3672119163287347287
Noncurrent Assets
Property, plant and equipment2223457
Intangible assets, net (including goodwill)4,8722,9594,8724,8724,8722,9594,872
Goodwill2,7232,7232,7232,7232,7232,7232,723
Intangible assets, net (excluding goodwill)2,1492362,1492,1492,1492362,149
Other undisclosed noncurrent assets 1,913   1,9130
Total noncurrent assets:4,8744,8744,8754,8754,8774,8784,879
TOTAL ASSETS:4,9104,9464,9945,0385,1645,2255,167
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5931,5911,6481,5831,5361,4221,178
Accounts payable 864 830801720570
Accrued liabilities 727 753735702608
Other undisclosed accounts payable and accrued liabilities1,593 1,648    
Debt331 258245235  
Due to related parties556550550550550550550
Other undisclosed current liabilities 265   1379
Total current liabilities:2,4802,4052,4562,3782,3212,1091,736
Noncurrent Liabilities
Liabilities, other than long-term debt     11 
Deferred tax liabilities, net 11 
Other undisclosed noncurrent liabilities3311 11  
Total noncurrent liabilities:3311 1111 
Total liabilities:2,4832,4092,4662,3782,3312,1201,736
Stockholders' equity
Stockholders' equity attributable to parent2,4262,5372,5272,6602,8333,1063,430
Common stock69696969696969
Additional paid in capital19,82719,78019,71019,63319,54019,41219,331
Accumulated deficit(17,470)(17,312)(17,252)(17,042)(16,777)(16,375)(15,970)
Total stockholders' equity:2,4262,5372,5272,6602,8333,1063,430
TOTAL LIABILITIES AND EQUITY:4,9104,9464,9945,0385,1645,2255,167

Income statement (P&L) ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Operating expenses(149)(61)(192)(263)(399)(405)(809)
Operating loss:(149)(61)(192)(263)(399)(405)(809)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(9)(7)(18)(2)(2)25
Interest and debt expense(9)(7)(21)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes9(21)21    
Loss from continuing operations before equity method investments, income taxes:(158)(95)(210)(265)(401)(403)(804)
Other undisclosed income from continuing operations before income taxes 28     
Loss from continuing operations before income taxes:(158)(68)(210)(265)(401)(403)(804)
Other undisclosed income (loss) from continuing operations 8   (2) 
Net loss available to common stockholders, diluted:(158)(60)(210)(265)(401)(405)(804)

Comprehensive Income ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Net loss:(158)(60)(210)(265)(401)(405)(804)
Comprehensive loss, net of tax, attributable to parent:(158)(60)(210)(265)(401)(405)(804)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: